S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

X4 Pharmaceuticals (XFOR) Stock Forecast, Price & News

-0.06 (-4.92%)
(As of 05/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
115,140 shs
Average Volume
156,471 shs
Market Capitalization
$35.75 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive XFOR News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

X4 Pharmaceuticals logo

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$3 million
Book Value
$1.61 per share


Net Income
$-88.70 million
Pretax Margin




Free Float
Market Cap
$35.75 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.16 out of 5 stars

Medical Sector

407th out of 1,416 stocks

Biological Products, Except Diagnostic Industry

64th out of 210 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

X4 Pharmaceuticals (NASDAQ:XFOR) Frequently Asked Questions

Is X4 Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" X4 Pharmaceuticals stock.
View analyst ratings for X4 Pharmaceuticals
or view top-rated stocks.

Are investors shorting X4 Pharmaceuticals?

X4 Pharmaceuticals saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 618,000 shares, a decline of 15.9% from the April 15th total of 734,900 shares. Based on an average daily trading volume, of 403,300 shares, the days-to-cover ratio is currently 1.5 days. Currently, 2.9% of the shares of the stock are sold short.
View X4 Pharmaceuticals' Short Interest

When is X4 Pharmaceuticals' next earnings date?

X4 Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for X4 Pharmaceuticals

How were X4 Pharmaceuticals' earnings last quarter?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) issued its earnings results on Thursday, May, 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.62) by $0.10. During the same quarter in the prior year, the firm posted ($1.30) earnings per share.
View X4 Pharmaceuticals' earnings history

What price target have analysts set for XFOR?

4 equities research analysts have issued 12-month price objectives for X4 Pharmaceuticals' shares. Their forecasts range from $7.00 to $27.00. On average, they anticipate X4 Pharmaceuticals' stock price to reach $12.08 in the next twelve months. This suggests a possible upside of 941.7% from the stock's current price.
View analysts' price targets for X4 Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are X4 Pharmaceuticals' key executives?
X4 Pharmaceuticals' management team includes the following people:
  • Dr. Paula Ragan Ph.D., Founder, CEO, Pres, Sec. & Director (Age 52, Pay $551.57k)
  • Mr. Adam S. Mostafa, CFO, Treasurer & Assistant Sec. (Age 42, Pay $400.56k) (LinkedIn Profile)
  • Mr. Derek M. Meisner Esq., J.D., Chief Legal Officer & Corp. Sec. (Age 51, Pay $479.46k) (LinkedIn Profile)
  • Dr. Mary DiBiase Ph.D., Chief Operating Officer
  • Dr. Arthur Taveras, Chief Scientific Officer
  • Dr. Glenn Schulman M.P.H., Pharm.D., VP of Investor Relations & Corp. Communications
  • Ms. Ronny Mosston M.B.A., Sr. VP of HR
  • Dr. Robert David Arbeit, Sr. VP of Clinical Devel. and Translational Research (Age 74)
  • Ms. Carrie Melvin M.B.A., Sr. VP of Devel. Operations
  • Dr. Diego Cadavid M.D., Chief Medical Officer (Age 56)
What other stocks do shareholders of X4 Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

What is X4 Pharmaceuticals' stock symbol?

X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR."

Who are X4 Pharmaceuticals' major shareholders?

X4 Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include AIGH Capital Management LLC (3.24%), Vanguard Group Inc. (2.12%), Worth Venture Partners LLC (0.81%), Simplex Trading LLC (0.00%), Renaissance Technologies LLC (0.56%) and Group One Trading L.P. (0.00%). Company insiders that own X4 Pharmaceuticals stock include Adam S Mostafa, Adam S Mostafa, Derek M Meisner, Derek M Meisner, Paula Ragan and Renato Skerlj.
View institutional ownership trends for X4 Pharmaceuticals

Which institutional investors are selling X4 Pharmaceuticals stock?

XFOR stock was sold by a variety of institutional investors in the last quarter, including AIGH Capital Management LLC, Vanguard Group Inc., Worth Venture Partners LLC, and Northern Trust Corp. Company insiders that have sold X4 Pharmaceuticals company stock in the last year include Adam S Mostafa, Derek M Meisner, and Paula Ragan.
View insider buying and selling activity for X4 Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying X4 Pharmaceuticals stock?

XFOR stock was acquired by a variety of institutional investors in the last quarter, including Simplex Trading LLC, Group One Trading L.P., Bank of New York Mellon Corp, Minot Wealth Management LLC, Jane Street Group LLC, Renaissance Technologies LLC, Virtu Financial LLC, and Cutler Group LP.
View insider buying and selling activity for X4 Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of X4 Pharmaceuticals?

Shares of XFOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is X4 Pharmaceuticals' stock price today?

One share of XFOR stock can currently be purchased for approximately $1.16.

How much money does X4 Pharmaceuticals make?

X4 Pharmaceuticals has a market capitalization of $35.75 million and generates $3 million in revenue each year. The company earns $-88.70 million in net income (profit) each year or ($3.460010) on an earnings per share basis.

How many employees does X4 Pharmaceuticals have?

X4 Pharmaceuticals employs 83 workers across the globe.

What is X4 Pharmaceuticals' official website?

The official website for X4 Pharmaceuticals is www.x4pharma.com.

How can I contact X4 Pharmaceuticals?

X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The company can be reached via phone at (857) 529-8300 or via email at [email protected].

This page was last updated on 5/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.